Skip to main content
. 2018 Feb 5;29:112–127. doi: 10.1016/j.ebiom.2018.02.001

Fig. 1.

Fig. 1

Progression-free survival by the expression of biomarkers in 2 cohorts of EGFR-mutation positive NSCLC patients. A. Median progression-free survival was 23.4 months (95% CI, 9.4 to 30.2) for the 21 patients with low AXL and 14.1 months (95% CI, 5.4 to 15.8) for the 21 patients with high AXL mRNA expression; p < 0.001 (Cohort 1). B. Median progression-free survival was 20.2 months (95% CI, 8.5 to 30.2) for the 24 patients with low CDCP1 and 9.1 months (95% CI, 4.5 to 14.2) for the 24 patients with high CDCP1 mRNA expression; p = 0.0179 (Cohort 1). C. Univariate analysis was performed in Cohort 1. The bars correspond to 95% confidence intervals. D. Combined AXL and CDCP1 mRNA expression higher than the median denotes a high-risk group with a median progression-free survival of 10.3 months (95%CI, 3.0 to 14.2) and combined AXL or CDCP1 mRNA expression lower than the median denotes a low-risk group with a median progression-free survival of 23.4 months (95% CI, 13.4 to 28.1); p = 0.0079 (Cohort 1). E. Median progression-free survival was 16.7 (95% CI, 11.1 to 22.0) for the 32 patients with low AXL and 10.7 (95% CI, 8.0 to 13.0) for the 21 patients with high AXL mRNA expression; p = 0.0025 (Cohort 2). F. Median progression-free survival was 16.7 months (95% CI, 11.0 to 22.0) for the 34 patients with low CDCP1 and 11.1 months (95% CI, 9.0 to 14.0) for the 19 patients with high CDCP1 mRNA expression; p = 0.0062 (Cohort 2). G. Univariate analysis was performed in Cohort 2. The bars correspond to 95% confidence intervals. H. Combined AXL and CDCP1 mRNA expression higher than the median denotes a high-risk group with a median progression-free survival of 10.7 months (95% CI, 7.2 to 14.8) and combined AXL or CDCP1 mRNA expression lower than the median denotes a low-risk group with a median progression-free survival of 15.0 months (95% CI, 11.1 to 19.5); p = 0.0192 (Cohort 2).